<DOC>
	<DOC>NCT00732186</DOC>
	<brief_summary>The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML</brief_summary>
	<brief_title>Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Ph+ CML on dasatinib therapy Loss of cytogenetic or molecular response while on dasatinib therapy On stable dose of dasatinib for a minimum of 12 weeks and with &lt; 14 day interruption of treatment Blast crisis CML Autoimmune disease Uncontrolled or significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>